Join us at the NEW Neuro Talk Theater
Visit the theater in HeadQuarters for more details about late-breaking science.
Learn, network and relax in the new Neuro Talk Theater. Located in the AHA HeadQuarters, Booth 528, in the Science and Technology Hall, this special learning experience will be open to all attendees on Wednesday and Thursday of the conference.
Morning programming includes unaccredited sessions from the AHA’s Stroke Council, Women in Science & Medicine, Fellows-in-Training and AHA Science.
Afternoon programming includes special Q&A sessions with the trialists from the Main Events’ Late-Breaking Science, including ESCAPE-MeVO, DISTAL, DISCOUNT, BEST, TRACE, PRESTIGE-AF, MIND, TRANSPORT2, ANGEL-TNK, ETERNAL-LVO, PEARL, ATIS-NVAF, LAMP and more! This is your opportunity to have your questions answered directly by the trialists from some of the most cutting-edge, impactful randomized stroke clinical trials this year.
Wednesday, Feb 5, Sessions
Leveraging Large Datasets for Stroke Research: An Introductory Session for Early Career Researchers
Shadi Yaghi and Alexis Simkins
9:10-9:40 a.m.
Strategies to Increase Diversity in Study Enrollment: Diverse Research Teams and Diverse Patients
Jose Gutierrez, Gail Cooksey, Sandi Shaw, Robert Araujo Contreras and Hooman Kamel
9:50-10:20 a.m.
Intersection of Posting and Pedagogy: Social Media in MedEd
James Siegler
10:30-11 a.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Endovascular Therapy Plus Best Medical Treatment Versus Best Medical Treatment Alone for Medium Distal Vessel Occlusion Stroke: The DISTAL Trial (LB3)
Marios Psychogios, University Hospital Basel, Urs Fischer, Inselspital, University Hospital Bern
2:50-3:10 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions: The ESCAPE-MeVO trial (LB4)
Mayank Goyal, University of Calgary, Michael Hill, University of Calgary
3:15-3:35 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion: Interim Analysis of the DISCOUNT Randomized Controlled Trial (LB47)
Frederic Clarencon, Pitié-Salpêtrière Hospital
3:40-4 p.m.
Thursday, Feb 6, Sessions
PROWESS Update: Advancing the Study of Stroke in Women
Eduard Valdes, Amy Yu, Valeria Caso, Tracy Madsen, Matthew Reeves and Virginia Howard
9:10-10:10 a.m.
Becoming Fellowship Director: Pathway to Education Leadership
Stacie L. Demel, Amanda L. Jagolino-Cole
10:30-11 a.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | TRANScranial Direct Current Stimulation for POst-Stroke Motor Recovery, a Phase II Study (TRANSPORT2): Main Results (LB16)
Wayne Feng, Duke University School of Medicine, Gottfried Schlaug, Bay State Health
2-2:20 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Intensive Blood Pressure Lowering After Thrombectomy in Ischemic Stroke Patients: A Randomized Clinical Trial (LB17)
Xuening Zhang, West China Hospital, Bo Wu, West China Hospital
2:25-2:45 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Coordinated, Collaborative, Comprehensive, Family-Based, Integrated, Technology-Enabled Post-Stroke Care (LB18)
George Howard, University of Alabama School of Public Health, Mark Alberts, Hartford HealthCare
2:50-3:10 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II Final Results (LB19)
Ken Butcher, University of New South Wales
3:15-3:35 p.m.
Open Q&A Session With the Main Event Late-Breaking Science Trialist(s) | Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial (LB20)
Issam Awad, University of Chicago Medical Center
3:40-4 p.m.
Visit the ISC 2025 Mobile Meeting App and Online Program Planner for more information on the Neuro Talk Theater’s programming and scheduling. We look forward to seeing you there.
